Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 365

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 365
---
 asset in exchange for non-cash lease liability from modification of lease                          | ​ | $                       |   3,417 | ​ | $ |        — | ​ | $ |       — |
| Transfer of property and equipment per lease assignment                                                                     | ​ | $                       |  -3,417 | ​ | $ |        — | ​ | $ |       — |
| Initial direct costs included as right-of-use asset from modification of lease                                              | ​ | $                       |     577 | ​ | $ |        — | ​ | $ |       — |
| Accrual for leasehold improvements                                                                                          | ​ | $                       |       — | ​ | $ |      778 | ​ | $ |       — |

See Notes to Consolidated Financial Statements.

F-55

#### CARA THERAPEUTICS, INC.​NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(amounts in thousands, except share and per share data)

#### 1.BusinessCara Therapeutics, Inc., or the Company, is a biopharmaceutical corporation formed onJuly 2, 2004. The Company has been focused on leading a new treatment paradigm to improve the lives of patients suffering from chronic pruritus. The Company’s primary activities to date have been organizing and staffing the Company, developing its lead product and product candidates, including conducting preclinical studies and clinical trials of difelikefalin-based product candidates, and raising capital.On June 14, 2024, the Board of Directors of the Company approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value after the Company announced its decision to discontinue the clinical program in notalgia paresthetica, or NP, on June 12, 2024. The Company’s decision to discontinue the clinical program in NP followed the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with NP in which oral difelikefalin did not demonstrate a meaningful clinical benefit at any dose compared to placebo. The Company’s decision was not related to any safety or medical issues, or negative regulatory feedback related to the Company’s NP program. In connection with the streamlined operating plan, the Board of Directors also approved a second reduction in the Company’s workforce by approximately70%, which the Company substantially completed in June 2024 (see Note 19,Commitments and Contingencies – Restruct